Adenovirus and adeno-associated virus vectors

DNA and Cell Biology

Volumn 21, Issue 12, 2002, Pages 895-913

  Lai, Chooi May ^a   Lai, Yvonne K Y ^b   Rakoczy, P Elizabeth ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b LIONS EYE INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; DNA BINDING PROTEIN; DNA POLYMERASE; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 52; HELICASE; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ADENO ASSOCIATED VIRUS; DIMERIZATION; GENE DELIVERY SYSTEM; GENE THERAPY; GENE TRANSFER; IMMUNOGENICITY; LIFE CYCLE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOGENICITY; PRIORITY JOURNAL; REVIEW; SAFETY; SEROTYPE; VIRUS CAPSID; VIRUS GENOME; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; CLINICAL TRIALS; DEFECTIVE VIRUSES; DEPENDOVIRUS; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GENOME, VIRAL; HUMANS; VIRUS REPLICATION;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; DNA VIRUSES;

EID: 0036968511     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454902762053855     Document Type: Review

References (279)

1. ACLAND, G.M., AGUIRRE, G.D., RAY, J., ZHANG, Q., ALEMAN, T.S., CIDECIYAN, A.V., PEARCE-KELLING, S.E., ANAND, V., ZENG, Y., MAQUIRE, et al. (2001). Gene therapy restores vision in a canine model of childhood blindness. Nat. Genet. 28, 92-95.
2. AKLI, S., CAILLAUD, C., VIGNE, E., STRATFORD-PERRICAUDET, L.D., POENARU, L., PERRICAUDET, M., KAHN, A., and PESCHANSKI, M.R. (1993). Transfer of a foreign gene into the brain using adenovirus vectors. Nat. Genet. 3, 224-228.
3. ALEXANDER, I.E., RUSSELL, D.W., and MILLER, A.D. (1994). DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J. Virol. 68, 8282-8287.
4. ALEXANDER, I.E., RUSSELL, D.W., SPENCE, A.M., and MILLER, A.D. (1996). Effects of gamma irradiation on the transduction of dividing and nondividing cells in brain and muscle of rats by adeno-associated virus vectors. Hum. Gene Ther. 7, 841-850.
5. ALI, R.R., REICHEL, M.B., THRASHER, A.J., LEVINSKY, R.J., KINNON, C., KANUGA, N., HUNT, D.M., and BHATTACHARYA, S.S. (1996). Gene transfer into the mouse retina mediated by an adeno-associated viral vector. Hum Mol. Genet. 5, 591-594.
6. ALI, R.R., SARRA, G.M., STEPHENS, C., ALWIS, M.D., BAINBRIDGE, J.W., MUNRO, P.M., FAUSER, S., REICHEL, M.B., KINNON, C., HUNT, D.M., et al. (2000). Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat. Genet. 25, 306-310.
7. ARMSTRONG, A.C., KERMINE S., ALLINSON, C.G., GHATTACHARYYA, T., MULRYAN, K., GONZALEZ, K.R., STERN, P.L., and HAWKINS, R.E. (2002). Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumour-protective immunity and identification of an idiotype-specific T cell epitope. J. Immunol. 168, 3983-3991.
8. ARRAND, J.R., and ROBERTS, R.J. (1979). The nucleotide sequences at the termini of adenovirus-2 DNA. J. Mol. Biol. 128, 577-594.
9. ASADA-MIKAMI, R., HEIKE, Y., KANAI, S., AZUMA, M., SHIRAKAWA, K., TAKAUE, Y., KRASNYKH, V., CURIEL, D., T., TERADA, M., ABE, T., and WAKASUGI, H. (2001). Efficient gene transduction by RGD-fiber modified recombinant adenovirus into dendritic cells. Jpn. J. Cancer Res. 92, 321-327.
10. AURICCHIO, A., KOBINGER, G., ANAND, V., HILDINGER, M., O'CONNOR, E., MAGUIRE, A.M., WILSON, J.M., and BENNETT, J. (2001). Exchange of surface proteins impacts on viral vector cellular specificity and transduction characteristics: the retina as a model. Hum. Mol. Genet. 10, 3075-3081.
11. BAJOCCHI, G., FELDMAN, S.H., CRYSTAL, R.G., and MASTRANGELI, A. (1993). Direct in vivo gene transfer to ependymal cells in the central nervous system using recombinant adenovirus vectors. Nat. Genet. 3, 229-234.
12. BALAGUE, C., KALLA, M., and ZHANG, W.W. (1997). Adeno-associated virus Rep78 proteha and terminal repeats enhance integration of DNA sequences into the cellular genome. J. Virol. 71, 3299-3306.
13. BARTLETT, J.S., KLEINSCHMIDT, J., BOUCHER, R.C., and SAMULSKI, R.J. (1999). Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab'gamma)2 antibody. Nat. Biotechnol. 17, 181-186.
14. BARTLETT, J.S., WILCHER, R., and SAMULSKI, R.J. (2000). Infectious entry pathway of adeno-associated virus and adeno-associated virus vectors. J. Virol. 74, 2777-2785.
15. BAUERSCHMITZ, G.J., LAM, J.T., KANERVA, A., SUZUKI, K., NETTELBECK, D.M., DMITRIEV, I., KRASNYKH, V., MIKHEEVA, G.V., BARNES, M.N., ALVAREZ, R.D., et al. (2002). Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res. 62, 1266-1270.
16. BAXI, M.K., DEREGT, D., ROBERTSON, J., BABIUK, L.A., SCHLAPP, T., and TIKOO, S.K. (2000). Recombinant bovine adenovirus type 3 expressing bovine viral diarrhea virus glycoprotein E2 induces an immune response in cotton rats. Virology 278, 234-243.
17. BENNETT, J., TANABE T., SUN, D., ZENG, Y., KJELDBYE, H., GOURAS, P., and MAGUIRE, A.M. (1996). Photoreceptor cell rescue in retinal degeneration (rd) mice by in vivo gene therapy. Nat. Med. 2, 649-654.
18. BERGELSON, J.M., CUNNINGHAM, J.A., DROGUETT, G., KURTJONES, E.A., KRITHIVAS, A., HONG, J.S., HORWITZ, M.S., CROWELL, R.L., and FINBERG, R.W. (1997). Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320-1323.
19. BERNS, K.I. (1990). Parvovirus replication. Microbiol. Rev. 54, 316-329.
20. BERNS, K.I. and GIRAUD, C. (1996). Biology of adeno-associated virus. In Adeno-associated Virus (AAV) Vectors in Gene Therapy. K. Berns and C. Giraud, eds. (Springer-Verlag, Berlin) pp. 1-24.
21. BETT, A.J., PREVEC, L., and GRAHAM, F.L. (1993). Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 67, 5911-5921.
22. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, J. A., SAMPSON-JOHANNES, A., et al. (1996). An adenovirus mutant that replicates selectively in p53 deficient human tumour cells. Science 274, 373-376.
23. BLACKWELL, J.L., LI, H., GOMEZ-NAVARRO, J., DMITRIEV, I., KRASNYKH, V., RICHTER, C.A., SHAW, D.R., ALVAREZ, R.D., CURIEL, D.T., and STRONG, T.V. (2000). Using a tropism-modified adenoviral vector to circumvent inhibitory factors in ascites fluid. Hum. Gene Ther. 11, 1657-1669.
24. BLACKWELL, J.L., MILLER, C.R., DOUGLAS, J.T., LI, H., REYNOLDS, P.N., CARROLL, W.R., PETERS, G.E., STRONG, T.V., and CURIEL, D.T. (1999). Retargeting to EGFR enhances adenovirus infection efficiency of squamous cell carcinoma. Arch. Otolaryngol. Head Neck Surg. 125, 856-863.
25. BOTH, G.W., LOCKETT, L.J., JANARDHANA, V., EDWARDS, S.J., BELLAMY, A.R., GRAHAM, F.L., PREVEC, L., and ANDREW, M.E. (1993). Protective immunity to rotavirus-induced diarrhoea is passively transferred to newborn mice from naive dams vaccinated with a single dose of a recombinant adenovirus expressing rotavirus VP7sc. Virology 193, 940-950.
26. BROCKSTEDT, D.G., PODSAKOFF, G.M., FONG, L., KURTZMAN, G., MUELLER-RUCHHOLTZ, W., and ENGLEMAN, E.G. (1999). Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration. Clin. Immunol. 92, 67-75.
27. BULLER, R.M., JANIK, J.E., SEBRING, E.D., and ROSE, J.A. (1981). Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J. Virol. 40, 241-247.
28. CASSIVI, S.D., LIU, M., BOEHLER, A., TANSWELL, A.K., SLUTSKY, A.S., KESHAVJEE, S., and TODD, S.T.R.J. (1999). Transgene expression after adenovirus-mediated retransfection of rat lungs is increased and prolonged by transplant immunosuppression. J. Thorac. Cardiovasc. Surg. 117, 1-7.
29. CASTO, B.C., ATCHISON, R.W., and HAMMON, W.M. (1967). Studies on the relationship between adeno-associated virus type I (AAV- 1) and adenoviruses. I. Replication of AAV-1 in certain cell cultures and its effect on helper adenovirus. Virology 32, 52-59.
30. CHAO, H., SAMULSKI, R., BELLINGER, D., MONAHAN, P., NICHOLS, T., and WALSH, C. (1999). Persistent expression of canine factor IX in haemophilia B canines. Gene Ther. 6, 1695-1704.
31. CHARDONNET, Y., and DALES, S. (1970). Early events in the interaction of adenoviruses with HeLa cells. I. Penetration of type 5 and intracellular release of the DNA genome. Virology 40, 462-477.
32. CHEJANOVSKY, N., and CARTER, B.J. (1989). Mutagenesis of an AUG codon in the adeno-associated virus rep gene: effects on viral DNA replication. Virology 173, 120-128.
33. CHIORINI, J.A., YANG, L., LIU, Y., SAFER, B., and KOTIN, R.M. (1997). Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J. Virol. 71, 6823-6833.
34. CHIRMULE, N., PROPERT, K., MAGOSIN, S., QIAN, Y., QIAN, R., and WILSON, J. (1999). Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther. 6, 1574-1583.
35. CHIRMULE, N., XIAO, W., TRUNEH, A., SCHNELL, M.A., HUGHES, J.V., ZOLTICK, P., and WILSON, J.M. (2000). Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J. Virol. 74, 2420-2425.
36. CHRISTENSON, S.D., LAKE, K.D., OOBOSHI, H., FARACI, F.M., DAVIDSON, B.L., and HEISTAD, D.D. (1998). Adenovirus-mediated gene transfer in vivo to cerebral blood vessels and perivascular tissue in mice. Stroke 29, 1411-1415.
37. CHROBOCZEK, J., BIEBER, F., and JACROT, B. (1992). The sequence of the genome of adenovirus type 5 and its comparison with the genome of adenovirus type 2. Virology 186, 280-285.
38. CONRAD, C.K., ALLEN, S.S., AFIONE, S.A., REYNOLDS, T.C., BECK, S.E., FEE-MAKI, M., BARRAZZA-ORTIZ, X., ADAMS, R., ASKIN, F.B., CARTER, B.J., et al. (1996). Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung. Gene Ther. 3, 658-668.
39. CORDIER, L., GAO, G.P., HACK, A.A., MCNALLY, E.M., WILSON, J.M., CHIRMULE, N., and SWEENEY, H.L. (2001). Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. Hum. Gene Ther. 12, 205-215.
40. CRIPE, T.P., DUNPHY, E.J., HOLUB, A.D., SAINI, A., VASI, N.H., MAHLLER, Y.Y., COLLINS, M.H., SNYDER, J.D., KRASNYKH, V., CURIEL, D.T., et al. (2001). Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. Cancer Res. 61, 2953-2960.
41. DAVIDSON, B.L., STEIN, C.S., HETH, J.A., MARTINS, I., KOTIN, R.M., DERKSEN, T.A., ZABNER, J., GHODSI, A., and CHIORINI, J.A. (2000). Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system. Proc. Natl. Acad. Sci. USA 97, 3428-3432.
42. DEMATTEO, R.P., CHU, G., AHN, M., CHANG, E., BARKER, C.F., and MARKMANN, J.F. (1997). Long-lasting adenovirus transgene expression in mice through neonatal intrathymic tolerance induction without the use of immunosuppression. J. Virol. 71, 5330-5335.
43. DEWAR, R.L., NATARAJAN, V., VASUDEVACHARI, M.B., and SALZMAN, N.P. (1989). Synthesis and processing of human immunodeficiency virus type 1 envelope proteins encoded by a recombinant human adenovirus. J. Virol. 63, 129-136.
44. DEWEESE, T.L., VAN DER, P.H., LI, S., MIKHAK, B., DREW, R., GOEMANN, M., HAMPER, U., DEJONG, R., DETORIE, N., RODRIGUEZ, R., HAULK, T., et al. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 61, 7464-7472.
45. DMITRIEV, I., KASHENTSEVA, E., ROGERS, B.E., KRASNYKH, V., and CURIEL, D.T. (2000). Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 74, 6875-6884.
46. DMITRIEV, I., KRASNYKH, V., MILLER, C.R., WANG, M., KASHENTSEVA, E., MIKHEEVA, G., BELOUSOVA, N., and CURIEL, D.T. (1998). An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J. Virol. 72, 9706-9713.
47. DONG, J.Y., FAN, P.D., and FRIZZELL, R.A. (1996). Quantitative analysis of the packaging capacity of recombinant adeno- associated virus. Hum. Gene Ther. 7, 2101-2112.
48. DORONIN, K., KUPPUSWAMY, M., TOTH, K., TOLLEFSON, A.E., KRAJCSI, P., KROUGLIAK, V., and WOLD, W.S. (2001). Tissue-specific, tumour-selective, replication-competent adenovirus vector for cancer gene therapy. J. Virol. 75, 3314-3324.
49. DOUAR, A.M., POULARD, K., STOCKHOLM, D., and DANOS, O. (2001). Intracellular trafficking of adeno-associated virus vectors: routing to the late endosomal compartment and proteasome degradation. J. Virol. 75, 1824-1833.
50. DOUGLAS, J.T., ROGERS, B.E., ROSENFELD, M.E., MICHAEL, S.I., FENG, M., and CURIEL, D.T. (1996). Targeted gene delivery by tropism-modified adenoviral vectors. Nat. Biotechnol. 14, 1574-1578.
51. DRIESSE, M.J., KROS, J.M., AVEZAAT, C.J., VALERIO, D., VECHT, C.J., BOUT, A., and SMITT, P.A. (1999). Distribution of recombinant adenovirus in the cerebrospinal fluid of nonhuman primates. Hum. Gene Ther. 10, 2347-2354.
52. DRITTANTI, L., RIVET, C., MANCEAU, P., DANOS, O., and VEGA, M. (2000). High throughput production, screening and analysis of adeno-associated viral vectors. Gene Ther. 7, 924-929.
53. DUAN, D., SHARMA, P., DUDUS, L., ZHANG, Y., SANLIOGLU, S., YAN, Z., YUE, Y., YE, Y., LESTER, R., YANG, J., et al. (1999). Formation of adeno-associated virus circular genomes is differentially regulated by adenovirus E4 ORF6 and E2a gene expression. J. Virol. 73, 161-169.
54. DUAN, D., YUE, Y., and ENGELHARDT, J.F. (2001). Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol. Ther. 4, 383-391.
55. DUAN, D., YUE, Y., YAN, Z., and ENGELHARDT, J.F. (2000a). A new dual-vector approach to enhance recombinant adeno-associated virus-mediated gene expression through intermolecular cis activation. Nat. Med. 6, 595-598.
56. DUAN, D., YUE, Y., YAN, Z., MCCRAY, P.B., JR., and ENGELHARDT, J.F. (1998). Polarity influences the efficiency of recombinant adeno-associated virus infection in differentiated airway epithelia. Hum. Gene Ther. 9, 2761-2776.
57. DUAN, D., YUE, Y., YAN, Z., YANG, J., and ENGELHARDT, J.F. (2000b). Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus. J. Clin. Invest. 105, 1573-1587.
58. DUDUS, L., ANAND, V., ACLAND, G.M., CHEN, S.J., WILSON, J.M., FISHER, K.J., MAGUIRE, A.M., and BENNETT, J. (1999). Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res. 39, 2545-2553.
59. DUONG, L.T., NAKAMURA, I., LAKKAKORPI, P.T., LIPFERT, L., BETT, A.J., and RODAN, G.A. (2001). Inhibition of osteoclast function by adenovirus expressing antisense protein-tyrosine kinase 2. J. Biol. Chem. 276, 7484-7492.
60. ENGELHARDT, J.F., YE, X., DORANZ, B., and WILSON, J.M. (1994). Ablation of E2A in recombinant adenoviruses improves transgene persistence and decreases inflammatory response in mouse liver. Proc. Natl. Acad. Sci. USA 91, 6196-6200.
61. ERLES, K., SEBOKOVA, P., and SCHLEHOFER, J.R. (1999). Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV). J. Med. Virol. 59, 406-411.
62. FABB, S.A., WELLS, D.J., SERPENTE, P., and DICKSON, G. (2002). Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofiber degeneration in nude/mdx mice. Hum. Mol. Genet. 11, 733-741.
63. FALGOUT, B. and KETNER, G. (1987). Adenovirus early region 4 is required for efficient virus particle assembly. J. Virol. 61, 3759-3768.
64. FERRARI, F.K., SAMULSKI, T., SHENK, T., AND SAMULSKI, R.J. (1996). Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J. Virol. 70, 3227-3234.
65. FISHER, K.J., CHOI, H., BURDA, J., CHEN, S.J., and WILSON, J.M. (1996a). Recombinant adenovirus deleted of all viral genes for gene therapy of cystic fibrosis. Virology 217, 11-22.
66. FISHER, K.J., GAO, G.P., WEITZMAN, M.D., DEMATTEO, R., BURDA, J.F., and WILSON, J.M. (1996b). Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J. Virol. 70, 520-532.
67. FISHER, K.J., JOOSS, K., ALSTON, J., YANG, Y., HAECKER, S.E., HIGH, K., PATHAK, R., RAPER, S.E., and WILSON, J.M. (1997). Recombinant adeno-associated virus for muscle directed gene therapy. Nat. Med. 3, 306-312.
68. FITZGERALD, D.J., PADMANABHAN, R., PASTAN, I., and WILLINGHAM, M.C. (1983). Adenovirus-induced release of epidermal growth factor and pseudomonas toxin into the cytosol of KB cells during receptor-mediated endocytosis. Cell 32, 607-617.
69. FLOTTE, T.R., AFIONE, S.A., CONRAD, C., MCGRATH, S.A., SOLOW, R., OKA, H., ZEITLIN, P.L., GUGGINO, W.B., AND CARTER, B.J. (1993). Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc. Natl. Acad. Sci. USA 90, 10613-10617.
70. GHOSH-CHOUDHURY, G., HAJ-AHMAD, Y., AND GRAHAM, F.L. (1987). Protein IX, a minor component of the human adenovirus capsid, is essential for the packaging of full length genomes. EMBO J 6, 1733-1739.
71. GILBERT, S.C., SCHNEIDER, J., HANNAN, C.M., HU, J.T., PLEBANSKI, M., SINDEN, R., and HILL, A.V. (2002). Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous primeboost immunisation regimes. Vaccine 20, 1039-1045.
72. GINSBERG, H.S. (ed). (1984). The Adenoviruses. (Plenum Press, New York).
73. GINSBERG, H.S., LUNDHOLM-BEAUCHAMP, U., HORSWOOD, R.L., PERNIS, B., WOLD, W.S., CHANOCK, R.M., and PRINCE, G.A. (1989). Role of early region 3 (E3) in pathogenesis of adenovirus disease. Proc. Natl. Acad. Sci. USA 86, 3823-3827.
74. GINSBERG, H.S., PEREIRA, H.G., VALENTINE, R.C., and WILCOX, W.C. (1966). A proposed terminology for the adenovirus antigens and virion morphological subunits. Virology 28, 782-783.
75. GOGEV, S., VANDERHEIJDEN, N., LEMAIRE, M., SCHYNTS, F., D'OFFAY, J., DEPREZ, I., ADAM, M., ELOIT, M., and THIRY, E. (2002). Induction of protective immunity to bovine herpesvirus type 1 in cattle by intranasal administration of replication-defective human adenovirus type 5 expressing glycoprotein gC or gD. Vaccine 20, 1451-1465.
76. GONZALEZ, R., VEREECQUE, R., WICKHAM, T.J., FACON, T., HETUIN, D., KOVESDI, I., BAUTERS, F., FENAUX, P., and QUESNEL, B. (1999a). Transduction of bone marrow cells by the AdZ.F(pK7) modified adenovirus demonstrates preferential gene transfer in myeloma cells. Hum. Gene Ther. 10, 2709-2717.
77. GONZALEZ, R., VEREECQUE, R., WICKHAM, T.J., VANRUMBEKE, M., KOVESDI, I., BAUTERS, F., FENAUX, P., and QUESNEL, B. (1999b). Increased gene transfer in acute myeloid leukemic cells by an adenovirus vector containing a modified fiber protein. Gene Ther. 6, 314-320.
78. GRAND, R.J. (1987). The structure and functions of the adenovirus early region 1 proteins. Biochem. J. 241, 25-38.
79. GREBER, U.F., WILLETTS, M., WEBSTER, P., and HELENIUS, A. (1993). Stepwise dismantling of adenovirus 2 during entry into cells. Cell 75, 477-486.
80. GREEN, E.S., RENDAHL, K.G., ZHOU, S., LADNER, M., COYNE, M., SRIVASTAVA, R., MANNING, W.C., and FLANNERY, J.G. (2001). Two animal models of retinal degeneration are rescued by recombinant adeno-associated virus-mediated production of FGF-5 and FGF-18. Mol. Ther. 3, 507-515.
81. GRIFMAN, M., TREPEL, M., SPEECE, P., GILBERT, L.B., ARAP, W., PASQUALINI, R., and WEITZMAN, M.D. (2001). Incorporation of tumour-targeting peptides into recombinant adeno- associated virus capsids. Mol. Ther. 3, 964-975.
82. GU, D.L., GONZALEZ, A.M., PRINTZ, M.A., DOUKAS, J., YING, W., D'ANDREA, M., HOGANSON, D.K., CURIEL, D.T., DOUGLAS, J.T., SOSNOWSKI, B.A., et al. (1999). Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumour activity in mice. Cancer Res. 59, 2608-2614.
83. GUENARD, V., SCHWEITZER, B., FLECHSIG, E., HEMMI, S., MARTINI, R., SUTER, U., and SCHACHNER, M. (1999). Effective gene transfer of lacZ and P0 into Schwann cells of P0- deficient mice. Glia 25, 165-178.
84. HABIB, N., SALAMA, H., ABD EL LATIF ABU MEDIAN, ISAC, A., I, ABD AL AZIZ, R. A., SARRAF, C., MITRY, R., HAVLIK, R., SETH, P., HARTWIGSEN, J., BHUSHAN, R., NICHOLLS, J., and JENSEN, S. (2002). Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. Cancer Gene Ther. 9, 254-259.
85. HACEIN-BEY-ABINA, S., LE DEIST, F., CARLIER, F., BOUNEAUD, C., HUE, C., DE VILLARTAY, J. P., THRASHER, A. J., WULFFRAAT, N., SORENSEN, R., DUPUIS-GIROD, S., et al. (2002). Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N. Engl. J. Med. 346, 1185-1193.
86. HAISMA, H.J., PINEDO, H.M., RIJSWIJK, A., DER MEULENMUILEMAN, I., SOSNOWSKI, B.A., YING, W., BEUSECHEM, V.W., TILLMAN, B.W., GERRITSEN, W.R., and CURIEL, D.T. (1999). Tumour-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther. 6, 1469-1474.
87. HALBERT, C.L., RUTLEDGE, E.A., ALLEN, J.M., RUSSELL, D.W., and MILLER, A.D. (2000). Repeat transduction in the mouse lung by using adeno-associated virus vectors with different serotypes. J. Virol. 74, 1524-1532.
88. HALBERT, D.N., CUTT, J.R., and SHENK, T. (1985). Adenovirus early region 4 encodes functions required for efficient DNA replication, late gene expression, and host cell shutoff. J. Virol. 56, 250-257.
89. HAMMOND, J.M., JANSEN, E.S., MORRISSY, C.J., WILLIAMSON, M.M., HODGSON, A.L., and JOHNSON, M.A. (2001). Oral and sub-cutaneous vaccination of commercial pigs with a recombinant porcine adenovirus expressing the classical swine fever virus gp55 gene. Arch. Virol. 146, 1787-1793.
90. HANDA, A., MURAMATSU, S., QIU, J., MIZUKAMI, H., and BROWN, K.E. (2000). Adeno-associated virus (AAV)-3-based vectors transduce haematopoietic cells not susceptible to transduction with AAV-2-based vectors. J. Gen. Virol. 81, 2077-2084.
91. HANSEN, J., QING, K., KWON, H.J., MAH, C., and SRIVASTAVA, A. (2000). Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts. J. Virol. 74, 992-996.
92. HANSEN, J., QING, K., and SRIVASTAVA, A. (2001a). Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts. J. Virol. 75, 4080-4090.
93. HANSEN, J., QING, K., and SRIVASTAVA, A. (2001b). Infection of purified nuclei by adeno-associated virus 2. Mol. Ther. 4, 289-296.
94. HARARI, O.A., WICKHAM, T.J., STOCKER, C.J., KOVESDI, I., SEGAL, D.M., HUEHNS, T.Y., SARRAF, C., and HASKARD, D.O. (1999). Targeting an adenoviral gene vector to cytokine-activated vascular endothelium via E-selectin. Gene Ther. 6, 801-807.
95. HARPER, S.Q., HAUSER, M.A., DELLORUSSO, C., DUAN, D., CRAWFORD, R.W., PHELPS, S.F., HARPER, H.A., ROBINSON, A.S., ENGELHARDT, J.F., BROOKS, S.V., and CHAMBERLAIN, J.S. (2002). Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat. Med. 8, 253-261.
96. HARTIGAN-O'CONNOR, D., AMALFITANO, A., and CHAMBERLAIN, J.S. (1999). Improved production of gutted adenovirus in cells expressing adenovirus preterminal protein and DNA polymerase. J. Virol. 73, 7835-7841.
97. HARTIGAN-O'CONNOR, D., BARJOT, C., CRAWFORD, R., and CHAMBERLAIN, J.S. (2002). Efficient rescue of gutted adenovirus genomes allows rapid production of concentrated stocks without negative selection. Hum. Gene Ther. 13, 519-531.
98. HARVEY, B.G., LEOPOLD, P.L., HACKETT, N.R., GRASSO, T.M., WILLIAMS, P.M., TUCKER, A.L., KANER, R.J., FERRIS, B., GONDA, I., SWEENEY, T.D., et al. (1999). Airway epithelial CFTR mRNA expression in cystic fibrosis patients after repetitive administration of a recombinant adenovirus. J. Clin. Invest. 104, 1245-1255.
99. HAUSWIRTH, W.W. and BEAUFRERE, L. (2000). Ocular gene therapy: quo vadis? Invest. Ophthalmol. Vis. Sci. 41, 2821-2826.
100. HEARING, P., SAMULSKI, R.J., WISHART, W.L., and SHENK, T. (1987). Identification of a repeated sequence element required for efficient encapsidation of the adenovirus type 5 chromosome. J. Virol. 61, 2555-2558.
101. HERMONAT, P.L., LABOW, M.A., WRIGHT, R., BERNS, K.I., and MUZYCZKA, N. (1984). Genetics of adeno-associated virus: isolation and preliminary characterization of adeno-associated virus type 2 mutants. J. Virol. 51, 329-339.
102. HERMONAT, P.L., PLOTT, R.T., SANTIN, A.D., PARHAM, G.P., and FLICK, J.T. (1997). Adeno-associated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric. Gynecol. Oncol. 66, 487-494.
103. HERNANDEZ, Y.J., WANG, J., KEARNS, W.G., LOILER, S., POIRIER, A., and FLOTTE, T.R. (1999). Latent adeno-associated virus infection elicits humoral but not cell- mediated immune responses in a nonhuman primate model. J. Virol. 73, 8549-8558.
104. HERZOG, R.W., YANG, E.Y., COUTO, L.B., HAGSTROM, J.N., ELWELL, D., FIELDS, P.A., BURTON, M., BELLINGER, D.A., READ, M.S., BRINKHOUS, K.M., et al. (1999). Long-term correction of canine haemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat. Med. 5, 56-63.
105. HOGGAN, M.D. (1970). Adenovirus associated viruses. Prog. Med. Virol. 12, 211-239.
106. HOGGAN, M.D., BLACKLOW, N.R., and ROWE, W.P. (1966). Studies of small DNA viruses found in various adenovirus preparations: physical, biological, and immunological characteristics. Proc. Natl. Acad. Sci. USA 55, 1467-1474.
107. HONG, G., WARD, P., and BERNS, K.I. (1992). In vitro replication of adeno-associated virus DNA. Proc. Natl. Acad. Sci. USA 89, 4673-4677.
108. HORWITZ, M.S. (1990). Adenoviridae and their replication. In Fundamental Virology. B.N. Fields and D.M. Knipe, eds. (Raven Press Ltd, New York) pp. 771-813.
109. HOWELL, J.M., LOCHMULLER, H., O'HARA, A., FLETCHER, S., KAKULAS, B.A., MASSIE, B., NALBANTOGLU, J., and KARPATI, G. (1998). High-level dystrophin expression after adenovirus-mediated dystrophin minigene transfer to skeletal muscle of dystrophic dogs: prolongation of expression with immunosuppression. Hum. Gene Ther. 9, 629-634.
110. HUGHES, S.M., MOUSSAVI-HARAMI, F., SAUTER, S.L., and DAVIDSON, B.L. (2002). Viral-mediated gene transfer to mouse primary neural progenitor cells. Mol. Ther. 5, 16-24.
111. ILAN, Y., DROGUETT, G., CHOWDHURY, N.R., LI, Y., SENGUPTA, K., THUMMALA, N.R., DAVIDSON, A., CHOWDHURY, J.R., and HORWITZ, M.S. (1997a). Insertion of the adenoviral E3 region into a recombinant viral vector prevents antiviral humoral and cellular immune responses and permits long-term gene expression. Proc. Natl. Acad. Sci. USA 94, 2587-2592.
112. ILAN, Y., JONA, V.K., SENGUPTA, K., DAVIDSON, A., HORWITZ, M.S., ROY-CHOWDHURY, N., and ROY-CHOWDHURY, J. (1997b). Transient immunosuppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviruses in the rat. Hepatology 26, 949-956.
113. ISHIBASHI, S., BROWN, M.S., GOLDSTEIN, J.L., GERARD, R.D., HAMMER, R.E., and HERZ, J. (1993). Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883-893.
114. IWAKAMI, S.I., SETOGUCHI, Y., SAIJO, Y., AZUMA, M., and FUKUCHI, Y. (2001). Replication-deficient adenovirus-mediated transfer of B7-1 (CD80) cDNA induces anti-tumour immunity in isolated human lung cancer. Respirology 6, 135-144.
115. JAAKKOLA, P., AHONEN, M., KAHARI, V.M., and JALKANEN, M. (2000). Transcriptional targeting of adenoviral gene delivery into migrating wound keratinocytes using FiRE, a growth factor-inducible regulatory element. Gene Ther. 7, 1640-1647.
116. JANIK, J.E., HUSTON, M.M., and ROSE, J.A. (1981). Locations of adenovirus genes required for the replication of adenovirus-associated virus. Proc. Natl. Acad. Sci. USA 78, 1925-1929.
117. JONES, N., and SHENK, T. (1979). An adenovirus type 5 early gene function regulates expression of oTher. early viral genes. Proc. Natl. Acad. Sci. USA 76, 3665-3669.
118. JOOSS, K., YANG, Y., FISHER, K.J., and WILSON, J.M. (1998). Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. J. Virol. 72, 4212-4223.
119. KALICHARRAN, K.K., SPRINGTHORPE, V.S., and SATTAR, S.A. (1992). Studies on the stability of a human adenovirus-rabies recombinant vaccine. Can. J. Vet. Res. 56, 28-33.
120. KALUDOV, N., BROWN, K.E., WALTERS, R.W., ZABNER, J., and CHIORINI, J.A. (2001). Adeno-associated virus serotype 4 (AAV4) and AAV5 both require sialic acid binding for hemagglutination and efficient transduction but differ in sialic acid linkage specificity. J. Virol. 75, 6884-6893.
121. KAMB, A., GRUIS, N.A., WEAVER-FELDHAUS, J., LIU, Q., HARSHMAN, K., TAVTIGIAN, S.V., STOCKERT, E., DAY, R.S., III, JOHNSON, B.E., and SKOLNICK, M.H. (1994). A cell cycle regulator potentially involved in genesis of many tumour types. Science 264, 436-440.
122. KANAZAWA, T., URABE, M., MIZUKAMI, H., OKADA, T., KUME, A., NISHINO, H., MONAHAN, J., KITAMURA, K., ICHIMURA, K., and OZAWA, K. (2001). Gamma-rays enhance rAAV-mediated transgene expression and cytocidal effect of AAV-HSVtk/ganciclovir on cancer cells. Cancer Gene Ther. 8, 99-106.
123. KAPLAN, J.M., ARMENTANO, D., SCARIA, A., WOODWORTH, L.A., PENNINGTON, S.E., WADSWORTH, S.C., SMITH, A.E., and GREGORY, R.J. (1999). Novel role for E4 region genes in protection of adenovirus vectors from lysis by cytotoxic T lymphocytes. J. Virol. 73, 4489-4492.
124. KAPLITT, M.G., LEONE, P., SAMULSKI, R.J., XIAO, X., PFAFF, D.W., O'MALLEY, K.L., and DURING, M.J. (1994). Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain. Nat. Genet. 8, 148-154.
125. KAPLITT, M.G., XIAO, X., SAMULSKI, R.J., LI, J., OJAMAA, K., KLEIN, I.L., MAKIMURA, H., KAPLITT, M.J., STRUMPF, R.K., and DIETHRICH, E.B. (1996). Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector Ann. Thorac. Surg. 62, 1669-1676.
126. KAY, M.A., LANDEN, C.N., ROTHENBERG, S.R., TAYLOR, L.A., LELAND, F., WIEHLE, S., FANG, B., BELLINGER, D., FINEGOLD, M., THOMPSON, A.R., et al. (1994). In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in haemophilia B dogs. Proc. Natl. Acad. Sci. USA 91, 2353-2357.
127. KELLY, T.J., JR. and LEWIS, A.M., JR. (1973). Use of nondefective adenovirus-simian virus 40 hybrids for mapping the simian virus 40 genome. J. Virol. 12, 643-652.
128. KIANMANESH, A., HACKETT, N.R., LEE, J.M., KIKUCHI, T., KORST, R.J., and CRYSTAL, R.G. (2001). Intratumoural administration of low doses of an adenovirus vector encoding tumour necrosis factor alpha togeTher. with naive dendritic cells elicits significant suppression of tumour growth without toxicity. Hum. Gene Ther. 12, 2035-2049.
129. KIRIK, D., GEORGIEVSKA, B., BURGER, C., WINKLER, C., MUZYCZKA, N., MANDEL, R.J., and BJORKLUND, A. (2002). Reversal of motor impairments in parkinsonian rats by continuous intrastriatal delivery of L-dopa using rAAV-mediated gene transfer. Proc. Natl. Acad. Sci. USA 99, 4708-4713.
130. KOCHANEK, S., CLEMENS, P.R., MITANI, K., CHEN, H.H., CHAN, S., and CASKEY, C.T. (1996). A new adenoviral vector: replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase. Proc. Natl. Acad. Sci. USA 93, 5731-5736.
131. KOTIN, R.M., LINDEN, R.M., and BERNS, K.I. (1992). Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J. 11, 5071-5078.
132. KOTIN, R.M., SINISCALCO, M., SAMULSKI, R.J., ZHU, X.D., HUNTER, L., LAUGHLIN, C.A., MCLAUGHLIN, S., MUZYCZKA, N., ROCCHI, M., and BERNS, K.I. (1990). Site-specific integration by adeno-associated virus. Proc. Natl. Acad. Sci. USA 87, 2211-2215.
133. KOZARSKY, K., GROSSMAN, M., and WILSON, J.M. (1993). Adenovirus-mediated correction of the genetic defect in hepatocytes from patients with familial hypercholesterolemia. Somat. Cell Mol. Genet. 19, 449-458.
134. KRASNYKH, V., BELOUSOVA, N., KOROKHOV, N., MIKHEEVA, G., and CURIEL, D.T. (2001). Genetic targeting of an adenovirus vector via replacement of the fiber protein with the phage T4 fibritin. J. Virol. 75, 4176-4183.
135. KRONENBERG, S., KLEINSCHMIDT, J.A., and BOTTCHER, B. (2001). Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep. 2, 997-1002.
136. KUBALL, J., WEN, S.F., LEISSNER, J., ATKINS, D., MEINHARDT, P., QUIJANO, E., ENGLER, H., HUTCHINS, B., MANEVAL, D.C., GRACE, M.J., et al. (2002). Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation. J. Clin. Oncol. 20, 957-965.
137. KUMAR-SINGH, R., and CHAMBERLAIN, J.S. (1996). Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells. Hum. Mol. Genet. 5, 913-921.
138. KUMAR-SINGH, R., and FARBER, D.B. (1998). Encapsidated adenovirus mini-chromosome-mediated delivery of genes to the retina: application to the rescue of photoreceptor degeneration. Hum. Mol. Genet. 7, 1893-1900.
139. LAI, Y.K., SHEN, W.Y., BRANKOV, M., LAI, C.M., CONSTABLE, I.J., and RAKOCZY, P.E. (2002). Potential long-term inhibition of ocular neovascularisation by recombinant adeno-associated virus-mediated secretion gene therapy. Gene Ther. 9, 804-813.
140. LALWANI, A.K., WALSH, B.J., CARVALHO, G.J., MUZYCZKA, N., and MHATRE, A.N. (1998). Expression of adeno-associated virus integrated transgene within the mammalian vestibular organs. Am. J. Otol. 19, 390-395.
141. LAMBRIGHT, E.S., AMIN, K., WIEWRODT, R., FORCE, S.D., LANUTI, M., PROPERT, K.J., LITZKY, L., KAISER, L.R., and ALBELDA, S.M. (2001). Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumour efficacy. Gene Ther. 8, 946-953.
142. LE GAL, L.S., ROBERT, J.J., BERRARD, S., RIDOUX, V., STRATFORD-PERRICAUDET, L.D., PERRICAUDET, M., and MALLET, J. (1993). An
143. LEE, M.G., ABINA, M.A., HADDADA, H., and PERRICAUDET, M. (1995). The constitutive expression of the immunomodulatory gp19k protein in E1-, E3- adenoviral vectors strongly reduces the host cytotoxic T cell response against the vector. Gene Ther. 2, 256-262.
144. LEES, C.Y., BRIGGS, D.J., WU, X., DAVIS, R.D., MOORE, S.M., GORDON, C., XIANG, Z., ERTL, H.C., TANG, D.C., and FU, Z.F. (2002). Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoprotein. Vet. Microbiol. 85, 295-303.
145. LIU, X., VOULGAROPOULOU, F., CHEN, R., JOHNSON, P.R., and CLARK, K.R. (2000). Selective Rep-Cap gene amplification as a mechanism for high-titer recombinant AAV production from stable cell lines. Mol. Ther. 2, 394-403.
146. LOWE, S.W., BODIS, S., MCCLATCHEY, A., REMINGTON, L., RULEY, H.E., FISHER, D.E., HOUSMAN, D.E., and JACKS, T. (1994). p53 status and the efficacy of cancer therapy in vivo. Science 266, 807-810.
147. MAH, C., QING, K., KHUNTIRAT, B., PONNAZHAGAN, S., WANG, X.S., KUBE, D.M., YODER, M.C., and SRIVASTAVA, A. (1998). Adeno-associated virus type 2-mediated gene transfer: role of epidermal growth factor receptor protein tyrosine kinase in transgene expression. J. Virol. 72, 9835-9843.
148. MAIONE, D., WIZNEROWICZ, M., DELMASTRO, P., CORTESE, R., CILIBERTO, G., LA MONICA, N., and SAVINO, R. (2000). Prolonged expression and effective readministration of erythropoietin delivered with a fully deleted adenoviral vector. Hum. Gene Ther. 11, 859-868.
149. MALIK, A.K., MONAHAN, P.E., ALLEN, D.L., CHEN, B.G., SAMULSKI, R.J., and KURACHI, K. (2000). Kinetics of recombinant adeno-associated virus-mediated gene transfer 7. J. Virol. 74, 3555-3565.
150. MANNING, W.C., ZHOU, S., BLAND, M.P., ESCOBEDO, J.A., and DWARKI, V. (1998). Transient immunosuppression allows transgene expression following readministration of adeno-associated viral vectors. Hum. Gene Ther. 9, 477-485.
151. MASHHOUR, B., COUTON, D., PERRICAUDET, M., and BRIAND, P. (1994). In vivo adenovirus-mediated gene transfer into ocular tissues. Gene Ther. 1, 122-126.
152. MCCOWN, T.J., XIAO, X., LI, J., BREESE, G.R., and SAMULSKI, R.J. (1996). Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res. 713, 99-107.
153. MCGEE SANFTNER, L.H., ABEL, H., HAUSWIRTH, W.W., and FLANNERY, J.G. (2001). Glial cell line derived neurotrophic factor delays photoreceptor degeneration in a transgenic rat model of retinitis pigmentosa. Mol. Ther. 4, 622-629.
154. MEYERS, C., ALAM, S., MANE, M., and HERMONAT, P. L. (2001). Altered biology of adeno-associated virus type 2 and human papillomavirus during dual infection of natural host tissue. Virology 287, 30-39.
155. MIAO, C.H., SNYDER, R.O., SCHOWALTER, D.B., PATIJN, G.A., DONAHUE, B., WINTHER, B., and KAY, M.A. (1998). The kinetics of rAAV integration in the liver. Nat. Genet. 19, 13-15.
156. MIYAZAKI, T., TAKAYANAGI, H., ISSHIKI, M., TAKAHASHI, T., OKADA, M., FUKUI, Y., ODA, H., NAKAMURA, K., HIRAI, H., KUROKAWA, T., and TANAKA, S. (2000). In vitro and in vivo suppression of osteoclast function by adenovirus vector-induced csk gene. J. Bone Miner. Res. 15, 41-51.
157. MIYAZAWA, N., LEOPOLD, P.L., HACKETT, N.R., FERRIS, B., WORGALL, S., FALCK-PEDERSEN, E., and CRYSTAL, R.G. (1999). Fiber swap between adenovirus subgroups B and C alters intracellular trafficking of adenovirus gene transfer vectors. J. Virol. 73, 6056-6065.
158. MORAES, M.P., MAYR, G.A., MASON, P.W., and GRUBMAN, M.J. (2002). Early protection against homologous challenge after a single dose of replication-defective human adenovirus type 5 expressing capsid proteins of foot-and-mouth disease virus (FMDV) strain A24. Vaccine 20, 1631-1639.
159. MORIN, J.E., LUBECK, M.D., BARTON, J.E., CONLEY, A.J., DAVIS, A.R., and HUNG, P.P. (1987). Recombinant adenovirus induces antibody response to hepatitis B virus surface antigen in hamsters. Proc. Natl. Acad. Sci. USA 84, 4626-4630.
160. MORSY, M.A., ALFORD, E.L., BETT, A., GRAHAM, F.L., and CASKEY, C.T. (1993). Efficient adenoviral-mediated ornithine transcarbamylase expression in deficient mouse and human hepatocytes. J. Clin. Invest. 92, 1580-1586.
161. MOSKALENKO, M., CHEN, L., VAN ROEY, M., DONAHUE, B.A., SNYDER, R.O., MCARTHUR, J.G., and PATEL, S.D. (2000). Epitope mapping of human anti-adeno-associated virus type 2 neutralizing antibodies: implications for gene therapy and virus structure. J. Virol. 74, 1761-1766.
162. MOTOI, F., SUNAMURA, M., DING, L., DUDA, D.G., YOSHIDA, Y., ZHANG, W., MATSUNO, S., and HAMADA, H. (2000). Effective gene therapy for pancreatic cancer by cytokines mediated by restricted replication-competent adenovirus. Hum. Gene Ther. 11, 223-235.
163. MULVIHILL, S., WARREN, R., VENOOK, A., ADLER, A., RANDLEV, B., HEISE, C., and KIRN, D. (2001). Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther. 8, 308-315.
164. MUNSHI, A., BYRNE, P., RAMESH, R., FREEMAN, S.M., and MARROGI, A.J. (1998). p53 molecule as a prognostic marker in human malignancies. J. La State Med. Soc. 150, 175-178.
165. MURAMATSU, S., FUJIMOTO, K., IKEGUCHI, K., SHIZUMA, N., KAWASAKI, K., ONO, F., SHEN, Y., WANG, L., MIZUKAMI, H., KUME, A., et al. (2002). Behavioral recovery in a primate model of Parkinson's disease by triple transduction of striatal cells with adeno-associated viral vectors expressing dopamine-synthesizing enzymes. Hum. Gene Ther. 13, 345-354.
166. NAGASAKI, Y., MATSUBARA, Y., TAKANO, H., FUJII, K., SENOO, M., AKANUMA, J., TAKAHASHI, K., KURE, S., HARA, M., KANEGAE, et al. (1999). Reversal of hypopigmentation in phenylketonuria mice by adenovirus-mediated gene transfer. Pediatr. Res. 45, 465-473.
167. NAKAI, H., IWAKI, Y., KAY, M.A., and COUTO, L.B. (1999). Isolation of recombinant adeno-associated virus vector-cellular DNA junctions from mouse liver. J. Virol. 73, 5438-5447.
168. NAKAI, H., STORM, T.A., and KAY, M.A. (2000a). Increasing the size of rAAV-mediated expression cassettes in vivo by intermolecular joining of two complementary vectors. Nat. Biotechnol. 18, 527-532.
169. NAKAI, H., STORM, T.A., and KAY, M.A. (2000b). Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J. Virol. 74, 9451-9463.
170. NAKAI, H., YANT, S.R., STORM, T.A., FUESS, S., MEUSE, L., and KAY, M.A. (2001). Extrachromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J. Virol. 75, 6969-6976.
171. NAVARRO, V., MILLECAMPS, S., GEOFFROY, M.C., ROBERT, J.J., VALIN, A., MALLET, J., and GAL LA SALLE, G.L. (1999). Efficient gene transfer and long-term expression in neurons using a recombinant adenovirus with a neuron-specific promoter. Gene Ther. 6, 1884-1892.
172. NEMUNAITIS, J., GANLY, I., KHURI, F., ARSENEAU, J., KUHN, J., MCCARTY, T., LANDERS, S., MAPLES, P., ROMEL, L., RANDLEV, B., et al. (2000). Selective replication and oncolysis in p53 mutant tumours with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. Cancer Res. 60, 6359-6366.
173. NI, T.H., ZHOU, X., MCCARTY, D.M., ZOLOTUKHIN, I., and MUZYCZKA, N. (1994). In vitro replication of adeno-associated virus DNA. J. Virol. 68, 1128-1138.
174. NICKLIN, S.A., BUENING, H., DISHART, K.L., DE ALWIS, M., GIROD, A., HACKER, U., THRASHER, A.J., ALI, R.R., HALLEK, M., and BAKER, A.H. (2001). Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol. Ther. 4, 174-181.
175. OHASHI, M., KANAI, F., TATEISHI, K., TANIGUCHI, H., MARIGNANI, P. A., YOSHIDA, Y., SHIRATORI, Y., HAMADA, H., and OMATA, M. (2001). Target gene therapy for alpha-fetoprotein-producing hepatocellular carcinoma by E1B55k-attenuated adenovirus. Biochem. Biophys. Res. Commun. 282, 529-535.
176. OKADA, Y., OKADA, N., NAKAGAWA, S., MIZUGUCHI, H., TAKAHASHI, K., MIZUNO, N., FUJITA, T., YAMAMOTO, A., HAYAKAWA, T., and MAYUMI, T. (2002). Tumour Necrosis Factor alpha-Gene Therapy for an Established Murine Melanoma Using RGD (Arg-Gly-Asp) Fiber-mutant Adenovirus Vectors. Jpn. J. Cancer Res. 93, 436-444.
177. OKAMOTO, A., DEMETRICK, D.J., SPILLARE, E.A., HAGIWARA, K., HUSSAIN, S.P., BENNETT, W.P., FORRESTER, K., GERWIN, B., SERRANO, M., BEACH, D.H., and HARRIS, C.C. (1994). Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA 91, 11045-11049.
178. PERRICONE, M.A., MORRIS, J.E., PAVELKA, K., PLOG, M.S., O'SULLIVAN, B.P., JOSEPH, P.M., DORKIN, H., LAPEY, A., BALFOUR, R., MEEKER, D.P., et al. (2001). Aerosol and lobar administration of a recombinant adenovirus to individuals with cystic fibrosis. II. Transfection efficiency in airway epithelium. Hum. Gene Ther. 12, 1383-1394.
179. + hematopoietic progenitor cells: donor variation and correlation of transgene expression with cellular differentiation. J. Virol. 71, 8262-8267.
180. PREVEC, L., CHRISTIE, B.S., LAURIE, K.E., BAILEY, M.M., GRAHAM, F.L., and ROSENTHAL, K.L. (1991). Immune response to HIV-1 gag antigens induced by recombinant adenovirus vectors in mice and rhesus macaque monkeys. J. Acquir. Immune Defic. Syndr. 4, 568-576.
181. PREVEC, L., SCHNEIDER, M., ROSENTHAL, K.L., BELBECK, L.W., DERBYSHIRE, J.B., and GRAHAM, F.L. (1989). Use of human adenovirus-based vectors for antigen expression in animals. J. Gen. Virol. 70, 429-434.
182. PRUCHNIC, R., CAO, B., PETERSON, Z.Q., XIAO, X., LI, J., SAMULSKI, R.J., EPPERLY, M., and HUARD, J. (2000). The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. Hum. Gene Ther. 11, 521-536.
183. QIAN, H.S., CHANNON, K., NEPLIOUEVA, V., WANG, Q., FINER, M., TSUI, L., GEORGE, S.E., and MCARTHUR, J. (2001). Improved adenoviral vector for vascular gene therapy: beneficial effects on vascular function and inflammation. Circ. Res. 88, 911-917.
184. QIAO, C., LI, J., SKOLD, A., ZHANG, X., and XIAO, X. (2002). Feasibility of generating adeno-associated virus packaging cell lines containing inducible adenovirus helper genes. J. Virol. 76, 1904-1913.
185. QING, K., HANSEN, J., WEIGEL-KELLEY, K.A., TAN, M., ZHOU, S., and SRIVASTAVA, A. (2001). Adeno-associated virus type 2-mediated gene transfer: role of cellular FKBP52 protein in transgene expression. J. Virol. 75, 8968-8976.
186. QING, K., KHUNTIRAT, B., MAH, C., KUBE, D.M., WANG, X.S., PONNAZHAGAN, S., ZHOU, S., DWARKI, V.J., YODER, M.C., and SRIVASTAVA, A. (1998). Adeno-associated virus type 2-mediated gene transfer: correlation of tyrosine phosphorylation of the cellular single-stranded D sequence-binding protein with transgene expression in human cells in vitro and murine tissues in vivo. J. Virol. 72, 1593-1599.
187. QING, K., MAH, C., HANSEN, J., ZHOU, S., DWARKI, V., and SRIVASTAVA, A. (1999). Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat. Med. 5, 71-77.
188. QING, K., WANG, X.S., KUBE, D.M., PONNAZHAGAN, S., BAJPAI, A., and SRIVASTAVA, A. (1997). Role of tyrosine phosphorylation of a cellular protein in adeno- associated virus 2-mediated transgene expression. Proc. Natl. Acad. Sci. USA 94, 10879-10884.
189. RABINOWITZ, J.E., ROLLING, F., LI, C., CONRATH, H., XIAO, W., XIAO, X., and SAMULSKI, R.J. (2002). Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity 584. J. Virol. 76, 791-801.
190. RABINOWITZ, J.E., XIAO, W., and SAMULSKI, R.J. (1999). Insertional mutagenesis of AAV2 capsid and the production of recombinant virus. Virology 265, 274-285.
191. RAGOT, T., VINCENT, N., CHAFEY, P., VIGNE, E., GILGENKRANTZ, H., COUTON, D., CARTAUD, J., BRIAND, P., KAPLAN, J.C., PERRICAUDET, M., and KAHN, A. (1993). Efficient adenovirus-mediated transfer of a human minidystrophin gene to skeletal muscle of mdx mice. Nature 361, 647-650.
192. REDDY, P.S., IDAMAKANTI, N., PYNE, C., ZAKHARTCHOUK, A.N., GODSON, D.L., PAPP, Z., BACA-ESTRADA, M.E., BABIUK, L.A., MUTWIRI, G.K., and TIKOO, S.K. (2000). The immunogenicity and efficacy of replication-defective and replication-competent bovine adenovirus-3 expressing bovine herpesvirus-1 glycoprotein gD in cattle. Vet. Immunol. Immunopathol. 76, 257-268.
193. REID, T., GALANIS, E., ABBRUZZESE, J., SZE, D., ANDREWS, J., ROMEL, L., HATFIELD, M., RUBIN, J., and KIRN, D. (2001). Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. Gene Ther. 8, 1618-1626.
194. REKOSH, D.M., RUSSELL, W.C., BELLET, A.J., and ROBINSON, A.J. (1977). Identification of a protein linked to the ends of adenovirus DNA. Cell 11, 283-295.
195. RICH, D.P., COUTURE, L.A., CARDOZA, L.M., GUIGGIO, V.M., ARMENTANO, D., ESPINO, P.C., HEHIR, K., WELSH, M.J., SMITH, A.E., and GREGORY, R.J. (1993). Development and analysis of recombinant adenoviruses for gene therapy of cystic fibrosis. Hum. Gene Ther. 4, 461-476.
196. ROBINSON, A.J., YOUNGHUSBAND, H.B., and BELLETT, A.J. (1973). A circula DNA-protein complex from adenoviruses. Virology 56, 54-69.
197. RODRIGUEZ, E., and EVERITT, E. (1996). Adenovirus uncoating and nuclear establishment are not affected by weak base amines. J. Virol. 70, 3470-3477.
198. ROLLING, F., SHEN, W.Y., TABARIAS, H., CONSTABLE, I., KANAGASINGAM, Y., BARRY, C.J., and RAKOCZY, P.E. (1999). Evaluation of adeno-associated virus-mediated gene transfer into the rat retina by clinical fluorescence photography. Hum. Gene Ther. 10, 641-648.
199. ROSEN, F.S. (2002). Successful gene therapy for severe combined immunodeficiency 1. N. Engl. J. Med. 346, 1241-1243.
200. ROSENFELD, M.A., YOSHIMURA, K., TRAPNELL, B.C., YONEYAMA, K., ROSENTHAL, E.R., DALEMANS, W., FUKAYAMA, M., BARGON, J., STIER, L.E., STRATFORD-PERRICAUDET, L., et al. (1992). In vivo transfer of the human cystic fibrosis transmembrane conductance regulator gene to the airway epithelium. Cell 68, 143-155.
201. ROWE, W.P., HUEBNER, R.J., GILMORE, L.K., PARROT, R.H., and WARD, T.G. (1953). Isolation of a cytopathogenic agent from human adenoids undergoing spontaneous degeneration in tissue culture. Proc. Soc. Exp. Bio. Med. 84, 570-573.
202. RUFFING, M., ZENTGRAF, H., and KLEINSCHMIDT, J.A. (1992). Assembly of viruslike particles by recombinant structural proteins of adeno-associated virus type 2 in insect cells. J. Virol. 66, 6922-6930.
203. RUTLEDGE, E.A., HALBERT, C.L., and RUSSELL, D.W. (1998). Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes oTher. than AAV type 2. J. Virol. 72, 309-319.
204. SAKAI, Y., KANEKO, S., NAKAMOTO, Y., KAGAYA, T., MUKAIDA, N., and KOBAYASHI, K. (2001). Enhanced anti-tumour effects of herpes simplex virus thymidine kinase/ganciclovir system by codelivering monocyte chemoattractant protein-1 in hepatocellular carcinoma. Cancer Gene Ther. 8, 695-704.
205. SAMULSKI, R.J., ZHU, X., XIAO, X., BROOK, J.D., HOUSMAN, D.E., EPSTEIN, N., and HUNTER, L.A. (1991). Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 10, 3941-3950.
206. SANLIOGLU, S., BENSON, P., and ENGELHARDT, J.F. (2000a). Loss of ATM function enhances recombinant adeno-associated virus transduction and integration through pathways similar to UV irradiation. Virology 268, 68-78.
207. SANLIOGLU, S., BENSON, P.K., YANG, J., ATKINSON, E.M., REYNOLDS, T., and ENGELHARDT, J.F. (2000b). Endocytosis and nuclear trafficking of adeno-associated virus type 2 are controlled by rac1 and phosphatidylinositol-3 kinase activation. J. Virol. 74, 9184-9196.
208. SANLIOGLU, S., DUAN, D., and ENGELHARDT, J.F. (1999). Two independent molecular pathways for recombinant adeno-associated virus genome conversion occur after UV-C and E4orf6 augmentation of transduction. Hum. Gene Ther. 10, 591-602.
209. SARUKHAN, A., CAMUGLI, S., GJATA, B., VON BOEHMER, H., DANOS, O., and JOOSS, K. (2001). Successful interference with cellular immune responses to immunogenic proteins encoded by recombinant viral vectors. J. Virol. 75, 269-277.
210. + cells. Hum. Gene Ther. 9, 2727-2734.
211. SEONG, Y.R., CHOI, S., LIM, J.S., LEE, C.H., LEE, C.K., and IM, D.S. (2001). Immunogenicity of the E1E2 proteins of hepatitis C virus expressed by recombinant adenoviruses. Vaccine 19, 2955-2964.
212. SETH, P., FITZGERALD, D., GINSBERG, H., WILLINGHAM, M., and PASTAN, I. (1984). Evidence that the penton base of adenovirus is involved in potentiation of toxicity of Pseudomonas exotoxin conjugated to epidermal growth factor. Mol. Cell Biol. 4, 1528-1533.
213. SHARPE, S., FOOKS, A., LEE, J., HAYES, K., CLEGG, C., and CRANAGE, M. (2002). Single oral immunization with replication deficient recombinant adenovirus elicits long-lived transgene-specific cellular and humoral immune responses. Virology 293, 210-216.
214. SHEN, W.Y., LAI, M.C., BEILBY, J., BARNETT, N.L., LIU, J., CONSTABLE, I.J., and RAKOCZY, P.E. (2001). Combined effect of cyclosporine and sirolimus on improving the longevity of recombinant adenovirus-mediated transgene expression in the retina. Arch. Ophthalmol. 119, 1033-1043.
215. SHEPPARD, M., WERNER, W., TSATAS, E., MCCOY, R., PROWSE, S., and JOHNSON, M. (1998). Fowl adenovirus recombinant expressing VP2 of infectious bursal disease virus induces protective immunity against bursal disease. Arch. Virol. 143, 915-930.
216. SHI, Z., ZENG, M., YANG, G., SIEGEL, F., CAIN, L.J., VAN KAMPEN, K.R., ELMETS, C.A., and TANG, D.C. (2001). Protection against tetanus by needle-free inoculation of adenovirus-vectore d nasal and epicutaneous vaccines. J. Virol. 75, 11474-11482.
217. SHISLER, J., YANG, C., WALTER, B., WARE, C.F., and GOODING, L.R. (1997). The adenovirus E3-10.4K/14.5K complex mediates loss of cell surface Fas (CD95) and resistance to Fas-induced apoptosis. J. Virol. 71, 8299-8306.
218. SHIVER, J.W., FU, T.M., CHEN, L., CASIMIRO, D.R., DAVIES, M.E., EVANS, R.K., ZHANG, Z.Q., SIMON, A.J., TRIGONA, W.L., DUBEY, S.A., et al. (2002). Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415, 331-335.
219. +) T-cell immunity and NK activity. Cancer Gene Ther. 8, 321-332.
220. SNYDER, R.O., MIAO, C., MEUSE, L., TUBB, J., DONAHUE, B.A., LIN, H.F., STAFFORD, D.W., PATEL, S., THOMPSON, A.R., NICHOLS, T., et al. (1999). Correction of haemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat. Med. 5, 64-70.
221. SNYDER, R.O., SPRATT, S.K., LAGARDE, C., BOHL, D., KASPAR, B., SLOAN, B., COHEN, L.K., and DANOS, O. (1997). Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Gene Ther. 8, 1891-1900.
222. SOLLERBRANT, K., ELMEN, J., WAHLESTEDT, C., ACKER, J., LEBLOIS-PREHAUD, H., LATTA-MAHIEU, M., YEH, P., and PERRICAUDET, M. (2001). A novel method using baculovirus-mediated gene transfer for production of recombinant adeno-associated virus vectors. J. Gen. Virol. 82, 2051-2060.
223. STABA, M.J., WICKHAM, T.J., KOVESDI, I., and HALLAHAN, D.E. (2000). Modifications of the fiber in adenovirus vectors increase tropism for malignant glioma models. Cancer Gene Ther. 7, 13-19.
224. STEENBERGH, P.H., MAAT, J., VAN ORMONDT, H., and SUSSENBACH, J.S. (1977). The nucleotide sequence at the termini of adenovirus type 5 DNA. Nucleic Acids Res. 4, 4371-4389.
225. STRATFORD-PERRICAUDET, L.D., MAKEH, I., PERRICAUDET, M., and BRIAND, P. (1992). Widespread long-term gene transfer to mouse skeletal muscles and heart. J. Clin. Invest. 90, 626-630.
226. SULLIVAN, N.J., SANCHEZ, A., ROLLIN, P.E., YANG, Z.Y., and NABEL, G.J. (2000). Development of a preventive vaccine for Ebola virus infection in primates. Nature 408, 605-609.
227. SUMMERFORD, C., BARTLETT, J.S., and SAMULSKI, R.J. (1999). AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nat. Med. 5, 78-82.
228. SUMMERFORD, C., and SAMULSKI, R.J. (1998). Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72, 1438-1445.
229. SUN, L., LI, J., and XIAO, X. (2000). Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. Nat. Med. 6, 599-602.
230. TIMMERMAN, J.M., CASPAR, C.B., LAMBERT, S.L., SYRENGELAS, A.D., and LEVY, R. (2001). Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 97, 1370-1377.
231. TIMS, T., BRIGGS, D.J., DAVIS, R.D., MOORE, S.M., XIANG, Z., ERTL, H. C., and FU, Z.F. (2000). Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies. Vaccine 18, 2804-2807.
232. TOLLEFSON, A.E., HERMISTON, T.W., LICHTENSTEIN, D.L., COLLE, C.F., TRIPP, R.A., DIMITROV, T., TOTH, K., WELLS, C.E., DOHERTY, P.C., and WOLD, W.S. (1998). Forced degradation of Fas inhibits apoptosis in adenovirus-infected cells. Nature 392, 726-730.
233. TRATSCHIN, J.D., MILLER, I.L., and CARTER, B.J. (1984). Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function. J. Virol. 51, 611-619.
234. TSUJINO, S., KINOSHITA, N., TASHIRO, T., IKEDA, K., ICHIHARA, N., KIKUCHI, H., HAGIWARA, Y., MIZUTANI, M., KIKUCHI, T., and SAKURAGAWA, N. (1998). Adenovirus-mediated transfer of human acid maltase gene reduces glycogen accumulation in skeletal muscle of Japanese quail with acid maltase deficiency. Hum. Gene Ther. 9, 1609-1616.
235. VANDERKWAAK, T.J., WANG, M., GOMEZ-NAVARRO, J., RANCOURT, C., DMITRIEV, I., KRASNYKH, V., BARNES, M., SIEGAL, G.P., ALVAREZ, R., and CURIEL, D.T. (1999). An advanced generation of adenoviral vectors selectively enhances gene transfer for ovarian cancer gene therapy approaches. Gynecol. Oncol. 74, 227-234.
236. VARGA, M.J., WEIBULL, C., and EVERITT, E. (1991). Infectious entry pathway of adenovirus type 2. J. Virol. 65, 6061-6070.
237. VASEY, P.A., SHULMAN, L.N., CAMPOS, S., DAVIS, J., GORE, M., JOHNSTON, S., KIRN, D.H., O'NEILL, V., SIDDIQUI, N., SEIDEN, M.V., and KAYE, S.B. (2002). Phase I trial of intraperitoneal injection of the E1B-55-kd-gene- deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. J. Clin. Oncol. 20, 1562-1569.
238. VERMEIJ, J., ZEINOUN, Z., NEYNS, B., TEUGELS, E., BOURGAIN, C., and DE GREVE, J. (2001). Transduction of ovarian cancer cells: a recombinant adeno-associated viral vector compared to an adenoviral vector. Br. J. Cancer 85, 1592-1599.
239. VOS, A., NEUBERT, A., POMMERENING, E., MULLER, T., DOHNER, L., NEUBERT, L., and HUGHES, K. (2001). Immunogenicity of an E1-deleted recombinant human adenovirus against rabies by different routes of administration. J. Gen. Virol. 82, 2191-2197.
240. WALZ, C.M., CORREA-OCHOA, M.M., MULLER, M., and SCHLEHOFER, J.R. (2002). Adenoassociated virus type 2-induced inhibition of the human papillomavirus type 18 promoter in transgenic mice. Virology 293, 172-181.
241. WANG, B., LI, J., and XIAO, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. USA 97, 13714-13719.
242. WATKINS, S.J., MESYANZHINOV, V.V., KUROCHKINA, L.P., and HAWKINS, R.E. (1997). The 'adenobody' approach to viral targeting: specific and enhanced adenoviral gene delivery. Gene Ther. 4, 1004-1012.
243. WEIDEN, M.D. and GINSBERG, H.S. (1994). Deletion of the E4 region of the genome produces adenovirus DNA concatemers. Proc. Natl. Acad. Sci. USA 91, 153-157.
244. WEINBERG, R.A. (1995). The retinoblastoma protein and cell cycle control. Cell 81, 323-330.
245. WEINDLER, F.W., and HEILBRONN, R. (1991). A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J. Virol. 65, 2476-2483.
246. WEN, S., DRISCOLL, R.M., SCHNEIDER, D.B., and DICHEK, D.A. (2001). Inclusion of the E3 region in an adenoviral vector decreases inflammation and neointima formation after arterial gene transfer. Arterioscler. Thromb. Vasc. Biol. 21, 1777-1782.
247. WEN, S., SCHNEIDER, D.B., DRISCOLL, R.M., VASSALLI, G., SASSANI, A.B., and DICHEK, D.A. (2000). Second-generation adenoviral vectors do not prevent rapid loss of transgene expression and vector DNA from the arterial wall. Arterioscler. Thromb. Vasc. Biol. 20, 1452-1458.
248. WESSELING, J.G., BOSMA, P.J., KRASNYKH, V., KASHENTSEVA, E.A., BLACKWELL, J.L., REYNOLDS, P.N., LI, H., PARAMESHWAR, M., VICKERS, S.M., JAFFEE, E.M., HUIBREGTSE, K., et al. (2001). Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther. 8, 969-976.
249. WICKHAM, T.J., LEE, G.M., TITUS, J.A., SCONOCCHIA, G., BAKACS, T., KOVESDI, I., and SEGAL, D.M. (1997a). Targeted adenovirus-mediated gene delivery to T cells via CD3. J. Virol. 71, 7663-7669.
250. WICKHAM, T.J., MATHIAS, P., CHERESH, D.A., and NEMEROW, G.R. (1993). Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 73, 309-319.
251. WICKHAM, T.J., ROELVINK, P.W., BROUGH, D.E., and KOVESDI, I. (1996a). Adenovirus targeted to heparan-containing receptors increases its gene delivery efficiency to multiple cell types. Nat. Biotechnol. 14, 1570-1573.
252. WICKHAM, T.J., SEGAL, D.M., ROELVINK, P.W., CARRION, M.E., LIZONOVA, A., LEE, G.M., and KOVESDI, I. (1996b). Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J. Virol. 70, 6831-6838.
253. WICKHAM, T.J., TZENG, E., SHEARS, L.L., ROELVINK, P.W., LI, Y., LEE, G.M., BROUGH, D.E., LIZONOVA, A., and KOVESDI, I. (1997b). Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 71, 8221-8229.
254. WILDNER, O., MORRIS, J.C., VAHANIAN, N.N., FORD, H., JR., RAMSEY, W.J., and BLAESE, R.M. (1999). Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. Gene Ther. 6, 57-62.
255. WOBUS, C.E., HUGLE-DORR, B., GIROD, A., PETERSEN, G., HALLEK, M., and KLEINSCHMIDT, J.A. (2000). Monoclonal antibodies against the adeno-associated virus type 2 (AAV-2) capsid: epitope mapping and identification of capsid domains involved in AAV-2-cell interaction and neutralization of AAV-2 infection. J. Virol. 74, 9281-9293.
256. WOLD, W.S. (1993). Adenovirus genes that modulate the sensitivity of virus-infected cells to lysis by TNF. J. Cell Biochem. 53, 329-335.
257. WONG, C.P. and LEVY, R. (2000). Recombinant adenovirus vaccine encoding a chimeric T-cell antigen receptor induces protective immunity against a T-cell lymphoma. Cancer Res. 60, 2689-2695.
258. WU, P., PHILLIPS, M.I., BUI, J., and TERWILLIGER, E.F. (1998). Adeno-associated virus vector-mediated transgene integration into neurons and oTher. nondividing cell targets. J. Virol. 72, 5919-5926.
259. WU, P., XIAO, W., CONLON, T., HUGHES, J., AGBANDJEMCKENNA, M., FERKOL, T., FLOTTE, T., and MUZYCZKA, N. (2000). Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism. J. Virol. 74, 8635-8647.
260. XIANG, Z., GAO, G., REYES-SANDOVAL, A., COHEN, C.J., LI, Y., BERGELSON, J.M., WILSON, J.M., and ERTL, H.C. (2002). Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J. Virol. 76, 2667-2675.
261. XIAO, W., CHIRMULE, N., BERTA, S.C., MCCULLOUGH, B., GAO, G., and WILSON, J.M. (1999). Gene therapy vectors based on adeno-associated virus type 1. J. Virol. 73, 3994-4003.
262. XIAO, X., LI, J., and SAMULSKI, R.J. (1996). Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J. Virol. 70, 8098-8108.
263. YAKINOGLU, A.O., HEILBRONN, R., BURKLE, A., SCHLEHOFER, J.R., and zur, H.H. (1988). DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res. 48, 3123-3129.
264. YAKOBSON, B., HRYNKO, T.A., PEAK, M.J., and WINOCOUR, E. (1989). Replication of adeno-associated virus in cells irradiated with UV light at 254 nm. J. Virol. 63, 1023-1030.
265. YAN, Z., RITCHIE, T.C., DUAN, D., and ENGELHARDT, J.F. (2002a). Recombinant AAV-mediated gene delivery using dual vector heterodimerization. Methods Enzymol. 346, 334-357.
266. YAN, Z., ZAK, R., LUXTON, G.W., RITCHIE, T.C., BANTELSCHAAL, U., and ENGELHARDT, J.F. (2002b). Ubiquitination of both adeno-associated virus type 2 and 5 capsid proteins affects the transduction efficiency of recombinant vectors. J. Virol. 76, 2043-2053.
267. YAN, Z., ZHANG, Y., DUAN, D., and ENGELHARDT, J.F. (2000). Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc. Natl. Acad. Sci. USA 97, 6716-6721.
268. YANG, J., ZHOU, W., ZHANG, Y., ZIDON, T., RITCHIE, T., and Engelhardt, J.F. (1999). Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J. Virol. 73, 9468-9477.
269. YANG, Q., MAMOUNAS, M., YU, G., KENNEDY, S., LEAKER, B., MERSON, J., WONG-STAAL, F., YU, M., and BARBER, J.R. (1998). Development of novel cell surface CD34-targeted recombinant adenoassociated virus vectors for gene therapy. Hum. Gene Ther. 9, 1929-1937.
270. YANG, Y., NUNES, F.A., BERENCSI, K., GONCZOL, E., ENGELHARDT, J.F., and WILSON, J. M. (1994). Inactivation of E2a in recombinant adenoviruses improves the prospect for gene therapy in cystic fibrosis. Nat. Genet. 7, 362-369.
271. YAP, J., O'BRIEN, T., TAZELAAR, H.D., and MCGREGOR, C.G. (1997). Immunosuppression prolongs adenoviral mediated transgene expression in cardiac allograft transplantation. Cardiovasc Res. 35, 529-535.
272. YAROSH, O.K., WANDELER, A.I., GRAHAM, F.L., CAMPBELL, J.B., and PREVEC, L. (1996). Human adenovirus type 5 vectors expressing rabies glycoprotein. Vaccine 14, 1257-1264.
273. YOON, S.K., ARMENTANO, D., WANDS, J.R., and MOHR, L. (2001). Adenovirus-mediated gene transfer to orthotopic hepatocellular carcinomas in athymic nude mice. Cancer Gene Ther. 8, 573-579.
274. YOSHIDA, T., OKUDA, K., XIN, K.Q., TADOKORO, K., FUKUSHIMA, J., TODA, S., HAGIWARA, E., HAMAJIMA, K., KOSHINO, T., and SAITO, T. (2001). Activation of HIV-1-specific immune responses to an HIV-1 vaccine constructed from a replication-defective adenovirus vector using various combinations of immunization protocols. Clin. Exp. Immunol. 124, 445-452.
275. YOUNG, S.M., JR., MCCARTY, D.M., DEGTYAREVA, N., and SAMULSKI, R.J. (2000). Roles of adeno-associated virus Rep protein and human chromosome 19 in site-specific recombination. J. Virol. 74, 3953-3966.
276. ZABNER, J., SEILER, M., WALTERS, R., KOTIN, R.M., FULGERAS, W., DAVIDSON, B.L., and CHIORINI, J.A. (2000). Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J. Virol. 74, 3852-3858.
277. ZAISS, A.K., LIU, Q., BOWEN, G.P., WONG, N.C., BARTLETT, J.S., and MURUVE, D.A. (2002). Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J. Virol. 76, 4580-4590.
278. ZHANG, Y., CHIRMULE, N., GAO, G., and WILSON, J. (2000). CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno- associated virus vectors in vivo: role of immature dendritic cells. J. Virol. 74, 8003-8010.
279. ZOLOTUKHIN, S., BYRNE, B.J., MASON, E., ZOLOTUKHIN, I., POTTER, M., CHESNUT, K., SUMMERFORD, C., SAMULSKI, R.J., and MUZYCZKA, N. (1999). Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther. 6, 973-985.